Loading…
Sectoral / Thematic · DSP Mutual Fund · AMFI code 145453DSP Healthcare Fund
Disclosed for 94 months, Dec 2018 to Sep 2026.
Portfolio value
₹291 Cr
up ₹12.7 Cr vs Jan 2020
- Stocks held
- 23
- unchanged
- Top 10 weight
- 59.6%
- of the portfolio in its ten largest
- Cash & debt
- 5.3%
- cash, money market and debt
- Moves this month
- 0 in · 0 out
- added to 10, trimmed 9
DSP Healthcare Fund is an active equity fund in the Sectoral / Thematic category from DSP Mutual Fund. In February 2020 it disclosed 23 stocks worth ₹291 Cr, up ₹12.7 Cr from Jan 2020. Its largest positions were IPCA Laboratories Limited (9.7%), Dr. Reddy's Laboratories Limited (8.9%), Divi's Laboratories Limited (7.5%); the ten largest together made up 59.6% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 66.5% of its equity. Cash and debt stood at 5.3%. Compared with Jan 2020 the fund entered 0 new stocks and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
82%
Top-10 weight is higher than 82% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
73%
Holds more cash than 73% of peers
What these mean: concentration · cash
Holdings in February 2020
Download CSVEvery line the fund disclosed, with the change against Jan 2020. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| IPCA Laboratories Limited | 9.65% | up 0.34 pts | ₹28.1 Cr | up ₹2.2 Cr | Added |
| Dr. Reddy's Laboratories Limited | 8.87% | down 1.00 pts | ₹25.8 Cr | down ₹1.7 Cr | Trimmed |
| Divi's Laboratories Limited | 7.55% | up 0.23 pts | ₹21.9 Cr | up ₹1.6 Cr | Added |
| JB Chemicals & Pharmaceuticals Limited | 7.35% | up 0.28 pts | ₹21.4 Cr | up ₹1.7 Cr | Added |
| Apollo Hospitals Enterprise Limited | 5.89% | down <0.01 pts | ₹17.1 Cr | up ₹75 L | Added |
| Indoco Remedies Limited | 5.40% | down 0.03 pts | ₹15.7 Cr | up ₹59 L | Added |
| Cash, TREPS & receivables | 5.31% | up 2.11 pts | ₹15.5 Cr | up ₹6.6 Cr | Added |
| Sun Pharmaceutical Industries Limited | 4.42% | down 0.96 pts | ₹12.8 Cr | down ₹2.1 Cr | Trimmed |
| Max India Limited | 3.66% | up 0.10 pts | ₹10.7 Cr | up ₹75 L | Added |
| Abbott India Limited | 3.41% | up 0.58 pts | ₹9.9 Cr | up ₹2 Cr | Added |
| Torrent Pharmaceuticals Limited | 3.37% | up 0.21 pts | ₹9.8 Cr | up ₹100 L | Added |
| Jubilant Pharmova Limited | 3.27% | down 0.67 pts | ₹9.5 Cr | down ₹1.4 Cr | Trimmed |
| Abbott Laboratories | 3.17% | up 0.12 pts | ₹9.2 Cr | up ₹75 L | Added |
| Ajanta Pharma Limited | 3.15% | up 0.51 pts | ₹9.2 Cr | up ₹1.8 Cr | Added |
| Alkem Laboratories Limited | 3.12% | up 0.14 pts | ₹9.1 Cr | up ₹79 L | Added |
| Alembic Pharmaceuticals Limited | 3.11% | down 0.15 pts | ₹9 Cr | down ₹1 L | Held |
| Syngene International Limited | 2.96% | down 0.28 pts | ₹8.6 Cr | down ₹39 L | Trimmed |
| Procter & Gamble Health Limited | 2.85% | down 0.30 pts | ₹8.3 Cr | down ₹48 L | Trimmed |
| Aarti Drugs Limited | 2.84% | up 0.21 pts | ₹8.3 Cr | up ₹93 L | Added |
| Narayana Hrudayalaya Limited | 2.59% | down 0.48 pts | ₹7.5 Cr | down ₹100 L | Trimmed |
| Dr. Lal Path Labs Limited | 2.45% | up 0.44 pts | ₹7.1 Cr | up ₹1.5 Cr | Added |
| Abiomed Inc | 2.42% | down 0.70 pts | ₹7.1 Cr | down ₹1.6 Cr | Trimmed |
| Unichem Laboratories Limited | 2.00% | down 0.58 pts | ₹5.8 Cr | down ₹1.4 Cr | Trimmed |
| ICICI Lombard General Insurance Company Limited | 1.17% | down 0.13 pts | ₹3.4 Cr | down ₹23 L | Trimmed |
What changed, Jan 2020 to Feb 2020
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- IPCA Laboratories Limitedup ₹2.2 Cr (+0.34% pts)
- Abbott India Limitedup ₹2 Cr (+0.58% pts)
- Ajanta Pharma Limitedup ₹1.8 Cr (+0.51% pts)
- JB Chemicals & Pharmaceuticals Limitedup ₹1.7 Cr (+0.28% pts)
- Divi's Laboratories Limited ₹1.6 Cr (+0.23% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jan 2020, the weight rose most in Pharmaceuticals & Biotechnology (+0.8 pts), and fell most in Healthcare Services (−0.5 pts) and Pharmaceuticals (−0.3 pts).
- Pharmaceuticals & Biotechnology65.6% → 66.5%+0.8 pts
- Healthcare Services21.6% → 21.1%−0.5 pts
- Pharmaceuticals11.4% → 11.2%−0.3 pts
- Insurance1.4% → 1.2%−0.1 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2019 | Aug 2019 | Nov 2019 | Jan 2020 | Feb 2020 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 72.7% | 70.1% | 69.0% | 65.6% | 66.5% |
| Healthcare Services | 14.6% | 17.1% | 19.1% | 21.6% | 21.1% |
| Pharmaceuticals | 10.4% | 11.1% | 10.4% | 11.4% | 11.2% |
| Insurance | 2.4% | 1.7% | 1.6% | 1.4% | 1.2% |
Allocation in Feb 2020change vs Jan 2020
- Pharmaceuticals & Biotechnology (13)66.5%▲ 0.8 pts
- Healthcare Services (6)21.1%▼ 0.5 pts
- Pharmaceuticals (3)11.2%▼ 0.3 pts
- Insurance (1)
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Feb 2020
5.3%
▲ 2.1 pts vs Jan 2020
- Cash alone
- 5.3%
- cash and net receivables
- A year earlier
- 13.1%
- Feb 2019 · now ▼ 7.8 pts
- Last 12 months
- 1.7% – 9.2%
- lowest to highest · record 28.6% in Dec 2018
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.